Abstract
To date, no IGF-1R targeting agent has shown clinical benefit in patients despite promising preclinical data. We hypothesized that Insulin-like growth factor binding protein-7 (IGFBP7) expression predicts response to Insulin-like growth factor-1 receptor (IGF-1R) targeting agents, for which there are no biomarkers predictive of efficacy. High IGFBP7 expression was previously associated with breast cancer progression. Therefore, the predictive value of IGFBP7 expression was interrogated in I-SPY2 (NCT01042379) for pathological complete response (pCR) to neoadjuvant treatment and in SCAN-B (NCT02306096) for clinical outcome. In I-SPY2, IGFBP7 expression was examined as a predictor of pCR to neoadjuvant chemotherapy alone and separately to the combination of chemotherapy plus ganitumab (anti-IGF-1R antibody) and metformin. Odds ratios (OR) and hazard ratios (HR) with 95% confidence interval (CI) were calculated with logistic and Cox regression, respectively. Higher IGFBP7 expression conferred lower odds of achieving pCR in the ganitumab/metformin plus chemotherapy arm, ORadj 0.38 (95% CI 0.17–0.80) but not in the chemotherapy-alone arm, adjusted OR 1.23 (95% CI 0.63–2.45; Pinteraction=0.016). In the ganitumab/metformin plus chemotherapy arm, 46.9% of patients with tumors in the lowest quartile of IGFBP7 expression achieved pCR compared to compared to only 5.6% in the highest quartile. In SCAN-B, higher IGFBP7 expression was associated with distant metastasis risk HRadj 1.41 (95% CI 1.16–1.73). In conclusion, low IGFBP7 gene expression identifies a subset of breast cancer patients for whom the addition of ganitumab and metformin to chemotherapy results in a significantly improved pCR rate compared to neoadjuvant chemotherapy alone. Furthermore, we add to prior evidence that high IGFBP7 expression is predictive of poor outcome.
Summary There has been a long-standing interest in targeting the Insulin-like growth factor-1 receptor (IGF-1R) signaling system in breast cancer due to its key role in growth, proliferation, and survival. To date, no IGF-1R targeting agent has shown substantial clinical benefit in controlled trials despite promising preclinical data. Treatment predictive biomarkers for IGF-1R targeting agents are lacking. IGFBP7 is an atypical insulin-like growth factor binding protein as it associates with the IGF-1R, reducing its capacity to bind IGF-1 or IGF-2. We report that low IGFBP7 gene expression identified a subset of breast cancers for which the addition of ganitumab (an anti-IGF-1R monoclonal antibody) with metformin to chemotherapy substantially improved the pathological complete response rate compared to neoadjuvant chemotherapy alone. Furthermore, high IGFBP7 expression predicted increased distant metastasis risk. IGFBP7 expression deserves further evaluation as a predictor of therapeutic benefit of IGF-1R targeting agents and of breast cancer prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01042379 and NCT02306096
Funding Statement
This study was funded by the Swedish Cancer Society (CAN 20 0763 and CAN 23 2952), the Faculty of Medicine at Lund University, the Mrs Berta Kamprad Foundation, and the South Swedish Health Care Region (Region Skane ALF 40620). Dr. Pollak acknowledges funding from the Terry Fox Foundation. The funders had no role in study design and conduct of the study, data collection and analysis, data interpretation, or manuscript preparation and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Clinical and RNA-seq data from SCAN-B is accessible from Staaf et al. 21, available at Mendeley Data. The clinical and transcriptomic data from I-SPY2 are available from the GEO database (GSE194040). This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available upon request. 21 Staaf, J., et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer 8, 94 (2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Clinical and RNA-seq data from SCAN-B is accessible from Staaf et al. 21, available at Mendeley Data. The clinical and transcriptomic data from I-SPY2 are available from the GEO database (GSE194040). This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available upon request. 21 Staaf, J., et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer 8, 94 (2022).
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE194040
Abbreviations
- DEGs
- Differentially expressed genes
- DGE
- Differential gene expression
- DMFI
- Distant metastasis-free interval
- ER
- Estrogen receptor
- EMT
- Epithelial-mesenchymal transition
- FC
- Fold change
- FDR
- False discovery rate
- FPKM
- Fragments per kilobase of exon per million mapped reads
- GEO
- Gene Expression Omnibus
- GEX
- Gene expression profile
- GSEA
- Gene set enrichment analysis
- HER2
- Human epidermal growth factor receptor 2
- HR
- Hazard ratio
- HR
- Hormone receptor
- IGF-1
- Insulin-like growth factor-1
- IGF-2
- Insulin-like growth factor-2
- IGFBP7
- Insulin-like growth factor receptor binding protein-7
- IGF-1R
- Insulin-like growth factor-1 receptor
- I-SPY2
- Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2
- OR
- Odds ratio
- OS
- Overall survival
- pCR
- pathological complete response
- PR
- Progesterone receptor
- RFI
- Recurrence-free interval
- RNA-seq
- Massive parallel paired-end sequencing of mRNA
- SCAN-B
- Swedish Cancerome Atlas Network - Breast
- TME
- Tumor microenvironment
- TNBC
- Triple-negative breast cancer
- Q
- Quartile